Increased levels of immunoreactive leukotriene B4 in blister fluids of bullous pemphigoid patients and effects of a selective 5-lipoxygenase inhibitor on experimental skin lesions - PubMed (original) (raw)
Affiliations
- PMID: 1977249
Increased levels of immunoreactive leukotriene B4 in blister fluids of bullous pemphigoid patients and effects of a selective 5-lipoxygenase inhibitor on experimental skin lesions
S Kawana et al. Acta Derm Venereol. 1990.
Abstract
The immunoreactive leukotriene B4 (i-LTB4) and i-LTC4 content in the blister fluids of patients with bullous pemphigoid (BP) was determined by radioimmunoassay. Their amounts significantly exceeded those noted in superficial dermal burn patients and those in the fluids of suction blisters produced on normal human skin. When either BP blister fluids or BP-IgG from the patient sera were injected into guinea pig skin, neutrophil and eosinophil infiltrates were produced in the dermis. In addition, the dermis was noted to undergo marked edematous change. A single oral administration of a selective inhibitor of 5-lipoxygenase 1 hr before the intracutaneous injection of BP-IgG was found to significantly inhibit cell infiltrates. Furthermore, the inhibitor partly suppressed dermal epidermal separation. On the basis of these results. LTB4 and LTC4 appear to be generated in the skin lesions of BP, the former attracting granulocytes to the dermis and the latter, causing exudation.
Similar articles
- [Leukotriene (LT) B4 and LTC4 in the blister fluid of bullous pemphigoid].
Kawana S, Nishiyama S. Kawana S, et al. Nihon Hifuka Gakkai Zasshi. 1989 May;99(6):659-64. Nihon Hifuka Gakkai Zasshi. 1989. PMID: 2555604 Japanese. - The Leukotriene B4 and its Receptor BLT1 Act as Critical Drivers of Neutrophil Recruitment in Murine Bullous Pemphigoid-Like Epidermolysis Bullosa Acquisita.
Sezin T, Krajewski M, Wutkowski A, Mousavi S, Chakievska L, Bieber K, Ludwig RJ, Dahlke M, Rades D, Schulze FS, Schmidt E, Kalies K, Gupta Y, Schilf P, Ibrahim SM, König P, Schwudke D, Zillikens D, Sadik CD. Sezin T, et al. J Invest Dermatol. 2017 May;137(5):1104-1113. doi: 10.1016/j.jid.2016.12.021. Epub 2017 Jan 17. J Invest Dermatol. 2017. PMID: 28108297 - Distinct compartmentalization of immune cells and mediators characterizes bullous pemphigoid disease.
Margaroli C, Bradley B, Thompson C, Brown MR, Giacalone VD, Bhatt L, Stoff B, Ahuja S, Springman E, Tirouvanziam R, Feldman RJ. Margaroli C, et al. Exp Dermatol. 2020 Dec;29(12):1191-1198. doi: 10.1111/exd.14209. Epub 2020 Oct 28. Exp Dermatol. 2020. PMID: 33047366 - [Bullous pemphigoid].
de Quatrebarbes J, Joly P. de Quatrebarbes J, et al. Rev Prat. 2005 Jun 15;55(11):1165-8. Rev Prat. 2005. PMID: 16164060 Review. French. - Eosinophils as putative therapeutic targets in bullous pemphigoid.
Simon D, Borradori L, Simon HU. Simon D, et al. Exp Dermatol. 2017 Dec;26(12):1187-1192. doi: 10.1111/exd.13416. Epub 2017 Oct 26. Exp Dermatol. 2017. PMID: 28833620 Review.
Cited by
- A Review of the Immunologic Pathways Involved in Bullous Pemphigoid and Novel Therapeutic Targets.
Afarideh M, Borucki R, Werth VP. Afarideh M, et al. J Clin Med. 2022 May 18;11(10):2856. doi: 10.3390/jcm11102856. J Clin Med. 2022. PMID: 35628982 Free PMC article. Review. - Dual inhibition of complement factor 5 and leukotriene B4 synergistically suppresses murine pemphigoid disease.
Sezin T, Murthy S, Attah C, Seutter M, Holtsche MM, Hammers CM, Schmidt E, Meshrkey F, Mousavi S, Zillikens D, Nunn MA, Sadik CD. Sezin T, et al. JCI Insight. 2019 Aug 8;4(15):e128239. doi: 10.1172/jci.insight.128239. eCollection 2019 Aug 8. JCI Insight. 2019. PMID: 31391346 Free PMC article. - The Autoimmune Skin Disease Bullous Pemphigoid: The Role of Mast Cells in Autoantibody-Induced Tissue Injury.
Fang H, Zhang Y, Li N, Wang G, Liu Z. Fang H, et al. Front Immunol. 2018 Mar 1;9:407. doi: 10.3389/fimmu.2018.00407. eCollection 2018. Front Immunol. 2018. PMID: 29545809 Free PMC article. Review. - Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model.
Liu Z, Sui W, Zhao M, Li Z, Li N, Thresher R, Giudice GJ, Fairley JA, Sitaru C, Zillikens D, Ning G, Marinkovich MP, Diaz LA. Liu Z, et al. J Autoimmun. 2008 Dec;31(4):331-8. doi: 10.1016/j.jaut.2008.08.009. Epub 2008 Oct 14. J Autoimmun. 2008. PMID: 18922680 Free PMC article. - The pathophysiology of bullous pemphigoid.
Kasperkiewicz M, Zillikens D. Kasperkiewicz M, et al. Clin Rev Allergy Immunol. 2007 Oct;33(1-2):67-77. doi: 10.1007/s12016-007-0030-y. Clin Rev Allergy Immunol. 2007. PMID: 18094948 Review.
MeSH terms
Substances
LinkOut - more resources
Medical